Stockscreener 앱 받기
0.387
7.50%
0.027
시간 외 거래:
.38
-0.007
-1.81%
전일 마감가:
$0.36
열려 있는:
$0.365
하루 거래량:
143.16K
Relative Volume:
0.75
시가총액:
$5.95M
수익:
-
순이익/손실:
$-19.09M
주가수익비율:
-0.1783
EPS:
-2.17
순현금흐름:
$-16.92M
1주 성능:
-3.27%
1개월 성능:
+4.88%
6개월 성능:
-34.13%
1년 성능:
-64.00%
1일 변동 폭
$0.35
$0.39
1주일 범위
$0.341
$0.4311
52주 변동 폭
$0.3154
$1.74
Organovo Holdings Inc Stock (ONVO) Company Profile
명칭
Organovo Holdings Inc
전화
858-224-1000
주소
11555 SORRENTO VALLEY ROAD, SAN DIEGO, CA
ONVO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ONVO
Organovo Holdings Inc
|
0.387 | 5.95M | 0 | -19.09M | -16.92M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Organovo Holdings Inc Stock (ONVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2018-12-13 | 개시 | H.C. Wainwright | Buy |
| 2017-11-10 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2017-01-25 | 개시 | Raymond James | Outperform |
| 2015-08-11 | 다운그레이드 | Cantor Fitzgerald | Buy → Hold |
| 2015-06-29 | 개시 | Jefferies | Buy |
| 2015-06-29 | 개시 | Piper Jaffray | Overweight |
모두보기
Organovo Holdings Inc 주식(ONVO)의 최신 뉴스
Organovo faces potential Nasdaq delisting - MSN
3D Bioprinting in Medical Market Worth $4.9 billion by 2032 | - openPR
Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com - Defense World
Organovo names new CFO amid clinical advancements By Investing.com - Investing.com Nigeria
Organovo Appoints Norman Staskey as Chief Financial Officer - citybiz
Organovo Announces Appointment of Norman Staskey as Chief Financial Officer - The Manila Times
Organovo names new CFO amid clinical advancements - Investing.com
Organovo Appoints M&A Veteran CFO as FXR314 Drug Shows Promising Phase 2 Results - StockTitan
Organovo (NASDAQ:ONVO) Coverage Initiated at StockNews.com - Defense World
Organovo appoints new president and CFO amid strategic plans By Investing.com - Investing.com Nigeria
Organovo appoints new president and CFO amid strategic plans - Investing.com India
Organovo Holdings Appoints Norman Staskey as New CFO - TipRanks
Organovo (NASDAQ:ONVO) Now Covered by StockNews.com - Defense World
Analyzing Sorrento Therapeutics (OTCMKTS:SRNEQ) and Organovo (NASDAQ:ONVO) - Defense World
Healthcare 4D Printing Market Top Companies Study3D Systems - openPR
3D Print Organ Market 2024 to Witness Huge Growth by 2032 Prominent Players are Organovo Holdings, EnvisionTEC - openPR
3D Bioprinting for Tissue and Organ Regeneration Market Top - openPR
3D Bioprinting Equipment Sales Market Overview, Future Trends - openPR
3D-Printed Organs Market is experiencing new opportunities & competitive edge highlighted by Top Market Key Players (Organovo Holdings Inc., Modern Meadow, Poietis, REGEMAT 3D S.L., Cellbricks, Nano3D Biosciences, Inc.) | Forecast to 2030 - Industry Today
Empowering Growth: Bioprinting Services Market 2024 - openPR
3D Bioprinting Market is Forecast to Achieve USD 2.0 Billion - openPR
ONVO (Organovo Holdings) Enterprise Value : $5.31 Mil (As of Dec. 01, 2024) - GuruFocus.com
Organovo expands equity incentive plan following stockholder approval By Investing.com - Investing.com Nigeria
Organovo expands equity incentive plan following stockholder approval - Investing.com
Organovo Holdings Gains Approval for Key Strategic Moves - TipRanks
Industrial 3D Printing Market Size Analysis and Top Companies - Precedence Research
ONVOOrganovo Holdings Inc. Latest Stock News & Market Updates - StockTitan
Organovo reports positive Phase 2 results for liver drug FXR314 By Investing.com - Investing.com Australia
Organovo reports positive Phase 2 results for liver drug FXR314 - Investing.com India
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting - The Manila Times
Organovo's FXR314 Shows Significant Liver Fat Reduction in Phase 2 MASH Trial | ONVO Stock News - StockTitan
Human Liver Models Market 2024-2031| Emerging Technologies, - openPR
Organovo stock plunges to 52-week low of $0.35 amid market challenges - Investing.com India
3D Bioprinting Market Projected to Reach $$$ Billion by 2031 with - openPR
Armistice Capital, LLC Increases Stake in Organovo Holdings Inc - GuruFocus.com
Global Organoids Market to Surge Significantly at a CAGR of ~14% by 2030 | DelveInsight - GlobeNewswire Inc.
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases - The Manila Times
Organovo's FXR314 Drug Trial Data Selected for Major Liver Conference Presentation | ONVO Stock News - StockTitan
3D Printer Market to Grow by USD 30 Billion (2024-2028), Driven by Rising Consumer Demand for Customized Products, AI-Powered Report Highlights Market TransformationTechnavio - The Malaysian Reserve
Is Health Care's Hottest Stock a Mirage? - AOL
Organovo: Fiscal Q2 Earnings Snapshot - San Antonio Express-News
Organovo Holdings Inc (ONVO) Quarterly 10-Q Report - Quartzy
Organovo stock plunges to 52-week low of $0.39 amid market challenges - Investing.com Australia
Organovo (NASDAQ:ONVO) Coverage Initiated by Analysts at StockNews.com - Defense World
Organovo stock plunges to 52-week low of $0.42 amid market challenges - Investing.com Canada
Organovo Holdings Inc (ONVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.65%
4.62%
자본화:
|
볼륨(24시간):